Using the assay, we conducted multifaceted characterizations of anti‐BCMA and APRIL‐based CAR T cell constructs against BCMA+ and BCMA knockout (KO) multiple myeloma MM.1s tumor cells. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.